

Table:

Within-trial analysis: Results from scenario analyses using discount rates of 30% and 50% applied to aflibercept and ranibizumab reflecting patient access schemes available in the UK ^aadjusted for baseline utility score

Discount of 30% applied to aflibercept and ranibizumab drug costs					
	Outcome	Intervention Mean (SD); N	Comparator Mean (SD); N	Difference ^a Mean (95% CI)	Probability CE £20000 (£30000)
Aflibercept vs Ranibizumab	Cost (£)	11,727 (2,900) ;154	10,893 (2,848) ;154	833 (203 to 1464)	-
	QALY	1.651 (0.2426) ;154	1.627 (0.2471) ;154	0.004 (-0.0430 to 0.0518)	-
	ICER (£)			189,133	0.11 (0.19)
Bevacizumab vs Ranibizumab	Cost (£)	6,227 (2,700) ;154	10,893 (2,848) ;154	-4,656 (-5,280 to -4,033)	-
	QALY	1.666 (0.2374) ;154	1.627 (0.2471) ;154	0.018 (-0.0282 to 0.0649)	-
	ICER (£)			Bevacizumab is dominant	1.00 (1.00)
Aflibercept vs Bevacizumab	Cost (£)	11,727 (2,900) ;154	6,227 (2,700) ;154	5,476 (4,837 to 6,116)	
	QALY	1.651 (0.2426) ;154	1.627 (0.2471) ;154	-0.015 (-0.0618 to 0.0322)	
	ICER (£)			Aflibercept is dominated	0.00 (0.00)
Discount of 50% applied to aflibercept and ranibizumab drug costs					
	Outcome	Intervention Mean (SD); N	Comparator Mean (SD); N	Difference ^a Mean (95% CI)	Probability CE £20000 (£30000)
Aflibercept vs Ranibizumab	Cost (£)	10,042 (2,553) ;154	9,499 (2,538) ;154	497 (-71 to 1,053)	-
	QALY	1.651 (0.2426) ;154	1.627(0.2471) ;154	0.004(-0.0430 to 0.0518)	-
	ICER (£)			111,622	0.24 (0.32)
Bevacizumab vs Ranibizumab	Cost (£)	6,201 (2,419) ;154	9,499 (2,538) ;154	-3,288 (-3,842 to -2,734)	-
	QALY	1.666 (0.2374) ;154	1.627(0.2471) ;154	0.018 (-0.0282 to 0.0649)	-
	ICER (£)			Bevacizumab is dominant	1.00 (1.00)

Aflibercept vs Bevacizumab	Cost (£)	10,042 (2,553) ;154	6,201 (2,419) ;154	3,809 (3,252 to 4,365)	-
	QALY	1.651 (0.2426)	1.666 (0.2374) ;154	-0.015 (-0.0618 to 0.0322)	-
	ICER (£)			Aflibercept dominated	is 0.00 (0.00)